Cresco Labs cites Pennsylvania dispensary acquisitions, Ohio adult-use lift as Q2 2026 revenue rises 5.9%
Margins and expenses were pressured
Gross profit increased 4.4% to USD 86.95 million; margin slipped to 50.2% from 50.9% on compressed mix from higher-margin states.
SG&A climbed 27.2% to USD 73.59 million on higher payroll tied to acquisitions, higher professional and legal fees; prior-year impairment did not repeat.
Adjusted EBITDA fell to USD 39.54 million from USD 40.88 million; interest expense rose to USD 15.11 million, lifting total other expense to USD 16.96 million.
Q2 revenue rose on Pennsylvania, Ohio and wholesale growth
For Q2 2026, revenue rose 5.9% to USD 173.34 million; growth came from Pennsylvania dispensary acquisitions, Ohio retail gains, Massachusetts and Ohio wholesale.
Pressure from reduced California operations; price compression and heavier competition in Illinois weighed on results.
